Suchergebnisse - (Standardsuche:ritonavir)

PubPharm (31)

1

Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir : data from the ICONA Cohort

enthalten in: HIV clinical trials | 2018

von d'Arminio Monforte, A. | Lorenzini, P. | Cozzi-Lepri, A. | +10

2

Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF

enthalten in: HIV clinical trials | 2017

von Harris, M. | Ganase, B. | Watson, B. | +5

3

Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine : OLE-LIP Substudy

enthalten in: HIV clinical trials | 2016

von Crespo, M. | Navarro, J. | Martinez-Rebollar, M. | +8

4

Regimen selection in the OPTIONS trial of HIV salvage therapy : drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity

enthalten in: HIV clinical trials | 2015

von Tashima, K. | Mollan, K. | Na, L. | +8

5

Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain : The TRIP study

enthalten in: HIV clinical trials | 2015

von Pedrol, E. | Caro-Murillo, A. | Castaño, M. | +11

6

Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients

enthalten in: HIV clinical trials | 2013

von Abgrall, S. | Le Bel, J. | Lele, N. | +60

7

Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142

enthalten in: HIV clinical trials | 2013

von Huang, J. | Hughes, M. | Riddler, S. | +2

8

Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART

enthalten in: HIV clinical trials | 2013

von Casado, J. | de Los Santos, I. | Del Palacio, M. | +4

9

Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial

enthalten in: HIV clinical trials | 2013

von Geretti, A. | Arribas, J. | Lathouwers, E. | +6

10

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects : the progress study, 48-week results

enthalten in: HIV clinical trials | 2011

von Reynes, J. | Lawal, A. | Pulido, F. | +6